Share

Prevention and Early Detection

ACS CAN advocates for public policies that can prevent nearly half of all cancer deaths by ensuring access to recommended cancer screenings, protecting the public from skin cancer risk, reducing tobacco use and exposure to secondhand smoke and supporting people in increasing physical activity, eating a healthy diet, and managing their weight.

Prevention and Early Detection Resources:

Critical steps are needed to increase lung cancer screening rates across the country and also increasing to access comprehensive cessation benefits, especially among individuals with limited incomes that are disproportionately burdened by lung cancer.

ACS CAN supports H.R. 4286 to eliminate barriers and increase access to lung cancer screening and expand coverage for tobacco cessation.

Breast cancer is the second most diagnosed cancer among women in the U.S. and the second leading cause of cancer death among women after lung cancer. Ensuring breast cancer screening services ― including diagnostic and follow-up testing ― are covered without no cost-sharing is essential to increasing access and expanding coverage of breast cancer screening.

ACS CAN supports H.R. 3086 to increase access to no cost breast cancer screening, diagnostic and follow-up testing.

The American Cancer Society Cancer Action Network (ACS CAN) supports a comprehensive approach to tobacco control that includes significantly increasing excise taxes on all tobacco products to generate revenue, protect kids, and save lives. Significant tobacco tax increases are one of the most effective ways to prevent kids from starting to use tobacco and help adults quit.

ACS CAN supports the Women and Lung Cancer Research and Preventive Services Act of 2023 by to accelerate progress in reducing mortality from lung cancer, including among women.

What children eat today affects their future cancer risks. Children with access to nutritious food are more likely to develop healthy eating habits they can continue to use into adulthood. Offering nutritious free school meals and snacks, before, during, and after school to all students is an effective policy intervention to address food insecurity and improve diet quality.

Our ability to continue to make progress against cancer relies heavily on eliminating inequities that exist in breast cancer prevention and treatment. That is why ACS CAN advocates for policies to reduce the disparities in breast cancer by improving access to prevention and early detection services, patient navigation services, insurance coverage, in-network facilities, and clinical trials.

In 1999, the U.S. Department of Justice (DOJ) filed a lawsuit against major tobacco manufacturers Philip Morris USA, R.J. Reynolds Tobacco, Lorillard, and Altria to hold the industry accountable for more than 50 years of conspiring to defraud the public in violation of the Racketeer Influenced and Corrupt Organizations (RICO) Act. Big Tobacco, an industry which has for decades knowingly addicted and endangered the lives of millions of Americans for their own profit, must now post the truth about their deadly products, including at the point-of-sale (POS) for approximately 220,000 tobacco retailers.

Sustained, dedicated federal investment in tobacco control through the Centers for Disease Control and Prevention’s Office of Smoking and Health (OSH) is necessary to prevent initiation of tobacco products, monitor tobacco product use, identify tobacco related disparities, and promote effective strategies to help individuals who use tobacco products to successfully quit.

Tobacco excise taxes benefit people with limited incomes and reduce tobacco-related health disparities, especially when tobacco excise tax revenues are dedicated to cessation programs that serve people with limited incomes.

Tobacco Control Resources:

The undersigned organizations write today to urge you to enforce the Congressionally-mandated deadlines for Premarket Tobacco Product Applications (PMTAs) for synthetic nicotine products and not allow any delays of those deadlines.

The undersigned organizations write today to urge you to enforce the Congressionally-mandated deadlines for Premarket Tobacco Product Applications (PMTAs) for synthetic nicotine products and not allow any delays of those deadlines.

High rates of menthol cigarette use is the result of deliberate actions by the tobacco industry to target certain populations. Decades of tobacco industry documents show how the tobacco industry targeted Black Americans, as well as LGBTQ+ and low-income communities with menthol cigarettes.

Cigars are tobacco wrapped in tobacco leaf or wrapped in a substance containing tobacco leaf. They can come in all shapes and sizes. One study found that the sales of cigarillos - which comprise most cigar sales - increased from 2016 to 2020 while their prices decreased. Lower prices can make tobacco products more attractive to youth because they are price sensitive. The study also found a significant increase in the sales of certain flavored cigarillos and large cigars.

Among adults who currently smoke cigars, those who used flavored products were more likely to be non-Hispanic Black individuals, younger, and have lower household incomes.

Flavors are a marketing ploy tobacco manufacturers use to target youth and young people to a lifetime of addiction. Adding flavors can improve the ease of use of a product by masking harsh effects, facilitating nicotine uptake, and increasing a product’s overall appeal.

This factsheet provides an overview of key activities by the FDA on menthol cigarettes and flavored cigars.

We write to urge you to respond to a new and growing threat to our nation’s youth: e-cigarette manufacturers’ use of synthetic nicotine to evade Food and Drug Administration (FDA) oversight. E-cigarette manufacturers, including the e-cigarette brand that is most popular with youth, are switching from using tobacco-derived nicotine in their products to synthetic nicotine in order to circumvent tobacco product regulations and to keep flavored e-cigarettes that are attracting and addicting youth on the market. We urge you to quickly address this serious public health situation by enacting legislation at the earliest possible opportunity that enables FDA’s Center for Tobacco Products to regulate synthetic nicotine products.

Whether Puff Bar is under the jurisdiction of the Center for Drug Evaluation and Research
(CDER) as a drug or the Center for Tobacco Products (CTP) as a tobacco product, it is critical that
FDA take action and not permit this company and this product to escape regulatory oversight.
Puff Bar has neither been approved as a drug nor received a premarket tobacco product order.
The agency should not allow any perceived regulatory “gap” to enable this company or any
other company to market new addictive nicotine products without going through the legally
required FDA review by either CDER or CTP.

Because JUUL’s products continue to have the largest share of the e-cigarette market, and therefore presumably are undergoing expedited review, we write at this time to express our conclusion that based on all of the publicly available evidence, no JUUL product currently on the market can meet the statutory public health standard. Therefore, they should not receive a marketing order.

Screening Resources:

Early detection of breast and cervical cancer through screening can improve survival and reduce mortality by finding cancer at an early stage when treatment is more effective and less expensive. To save lives and reduce health care spending, the Centers for Disease Control and Prevention’s (CDC) National Breast and Cervical Cancer Early Detection Program (NBCCEDP) is highly effective at detecting and treating breast and cervical cancer in people who may otherwise not be screened.

Early detection of cancer through screening can improve survival and reduce mortality by detecting cancer at an early stage when treatment is more effective. The most recent data show breast and lung cancer screening rates were lowest among American Indian and Alaska Native people compared to other race and ethnicities, and below all race and ethnicities combined for cervical, colorectal, and prostate cancer screening.

The Centers for Disease Control and Prevention’s (CDC) National Breast and Cervical Cancer Early Detection Program (NBCCEDP) is highly effective at detecting and treating breast and cervical cancer in low-income, uninsured, and underinsured women – who may otherwise not be screened. The American Cancer Society Cancer Action Network (ACS CAN) urges Congress to reauthorize this critical program by passing the Screening for Communities to Receive Early and Equitable Needed Services (SCREENS) for Cancer Act.

For 30 years, the Centers for Disease Control and Prevention’s National Breast and Cervical Cancer Early Detection Program has decreased disparities in breast and cervical cancer deaths.

In 2024, an estimated 13,820 people in the U.S. will be diagnosed with invasive cervical cancer, and 4,360 will die from the disease. Cervical cancer can affect any person with a cervix and most often is caused by certain types of human papillomavirus (HPV). Persistent HPV infection causes almost all cervical cancers but fortunately there is a safe and effective vaccine against HPV.

The PSA Screening for HIM Act  (H.R. 1826/S. 2821) would remove out-of-pocket costs for prostate cancer screening for those at highest risk for the disease. 

Approximately 1 in 8 women (13%) will be diagnosed with invasive breast cancer in her lifetime, and 1 in 39 women (3%) will die from breast cancer. In 2023, an estimated 297,790 women in the U.S. will be diagnosed with invasive breast cancer, and 43,170 will die from the disease. Despite the fact that U.S. breast cancer death rates have been declining for several decades, not all people have benefited equally from the advances in prevention, early detection, and treatments that have helped achieve these lower rates.

Critical steps are needed to increase lung cancer screening rates across the country and also increasing to access comprehensive cessation benefits, especially among individuals with limited incomes that are disproportionately burdened by lung cancer.

ACS CAN supports H.R. 4286 to eliminate barriers and increase access to lung cancer screening and expand coverage for tobacco cessation.

Breast cancer is the second most diagnosed cancer among women in the U.S. and the second leading cause of cancer death among women after lung cancer. Ensuring breast cancer screening services ― including diagnostic and follow-up testing ― are covered without no cost-sharing is essential to increasing access and expanding coverage of breast cancer screening.

ACS CAN supports H.R. 3086 to increase access to no cost breast cancer screening, diagnostic and follow-up testing.

Healthy Eating and Active Living Resources:

ACS and ACS CAN submitted comments and recommendations regarding the White House Conference on Hunger, Nutrition, and Health, planned to be held in September 2022. 

ACS and ACS CAN submitted comments on Topics and Scientific Questions for the 2025-2030 Dietary Guidelines for Americans. 

  •